Buxton, M., Alexander, B., Berry, D., Cavenee, W., Colman, H., de Groot, J., … Cloughesy, T. (2020). GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA. In NEURO-ONCOLOGY (Vol. 22, pp. 195–196).

Buxton, Meredith, Brian Alexander, Donald Berry, Webster Cavenee, Howard Colman, John de Groot, Benjamin Ellingson, et al. “GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA.” In NEURO-ONCOLOGY, 22:195–96, 2020.

Buxton M, Alexander B, Berry D, Cavenee W, Colman H, de Groot J, et al. GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA. In: NEURO-ONCOLOGY. 2020. p. 195–6.

Buxton, Meredith, et al. “GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA.” NEURO-ONCOLOGY, vol. 22, 2020, pp. 195–96.

Buxton M, Alexander B, Berry D, Cavenee W, Colman H, de Groot J, Ellingson B, Gordon G, Khasraw M, Lassman A, Lee W, Lim M, Mellinghoff I, Perry J, Sulman E, Tanner K, Weller M, Wen P, Yung WKA, Cloughesy T. GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA. NEURO-ONCOLOGY. 2020. p. 195–196.